[EN] HETEROCYCLYL COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE<br/>[FR] COMPOSÉS HÉTÉROCYCLYLES POUR LE TRAITEMENT D'UNE MALADIE AUTO-IMMUNE
申请人:HOFFMANN LA ROCHE
公开号:WO2020064792A1
公开(公告)日:2020-04-02
The present invention relates to compounds of formula (I), wherein R1 to R3, A and Q are as described herein, and their pharmaceutically acceptable salt, enantiomer or diastereomer thereof, and compositions including the compounds and methods of using the compounds.
[EN] DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS<br/>[FR] DÉRIVÉS DE QUINOLÉINES ET DE QUINOXALINES EN TANT QU'INHIBITEURS DE PROTÉINE TYROSINE KINASES
申请人:NOVARTIS AG
公开号:WO2009141386A1
公开(公告)日:2009-11-26
The invention relates to compounds of Formula (I), wherein the substituens are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.
A metal-free direct ammoxidation of readily available methyl arenes leading to nitriles was established under mild conditions.
一种无金属直接氨氧化可获得的甲基芳烃制备腈的方法在温和条件下建立。
Novel Materials for Organic Electroluminescent Devices
申请人:Vestweber Horst
公开号:US20080220285A1
公开(公告)日:2008-09-11
The present invention relates to the improvement of organic electroluminescent devices, in particular blue-emitting devices, by using compounds of the formula (1) as dopants in the emitting layer.
本发明涉及利用式(1)化合物作为发光层杂质,改善有机电致发光装置,特别是蓝色发射装置。
Quinoxaline- and Quinoline-Carboxamide Derivatives
申请人:FURET Pascal
公开号:US20100105667A1
公开(公告)日:2010-04-29
The invention relates to compounds of formula (I)
wherein the substituents are as defined in the specification, in free form or in the form of a pharmaceutically acceptable salt, solvate, ester, N-oxide thereof; processes for the preparation thereof; to pharmaceuticals containing such compounds, in particular for the use in one or more Protein tyrosine kinase mediated diseases.